TRANSLATIONAL ONCOLOGY PROGRAM

转化肿瘤学（TO）项目的使命是开展临床试验，促进基础科学家、转化科学家和临床医生之间的互动，以促进改善临床结果。在上次审查期间，该方案被组织成以下三个专题领域，这些领域在特定疾病工作组中得到强调：(1)开发和开展早期临床试验，目标是将研究结果转化为合作小组或第三阶段环境；(2)促进在临床试验中纳入预测性和预后生物标志物概况；(3)开发与抗血管生成药物、信号通路和活性氧（ROS）相关的新治疗方法。为了促进方案间和方案内的相互作用和转化活动，最近为黑色素瘤、乳腺癌、Gl、前列腺癌和宫颈癌/妇科癌症建立了特定疾病转化工作组（twg）。通过与其他项目的合作，包括肿瘤成像（新辅助乳腺）和肿瘤发生与信号传导（CML，前列腺），与翻译终点相结合的临床试验已经发展起来。在过去的五年中，我们的项目一直专注于临床研究试验，包括假设驱动的、研究者发起的试验（HDII）、合作小组和制药赞助的试验。重点放在HDII试验上，以利用UCI丰富的综合癌症中心资源来开发癌症治疗的新方法。过去6年，HDII累计数量已从2002-2004年的60笔大幅增长至2005-2007年的175笔。总的干预性临床试验（不包括化学预防试验）在2002-2003年为142项，2004-2005年增加到218项，2005-2007年迄今为止为387项。特别重要的是，这种增长与翻译终点有关，这导致了同行评议的资助和高影响力期刊上出版物数量的增加。

The Translational Oncology (TO) Program's mission is to develop clinical trials that promote interaction between basic scientists, translational scientists, and clinicians to facilitate improved clinical outcomes. During the last review period the Program was organized into the following three thematic areas that are emphasized in disease-specific working groups: (1) Develop and carry out early phase clinical trials with a goal to translate findings into the cooperative group or phase III setting; (2) Facilitate inclusion of predictive and prognostic biomarker profiles in clinical trials; (3) Develop novel therapeutic approaches related to antiangiogenesis agents, signaling pathways and reactive oxygen species (ROS). In order to promote interprogrammatic and intra-programmatic interactions and translational activities, disease specific translational working groups (TWGs) were recently established for melanoma, breast, Gl, prostate and cervical/GYN cancers. Clinical trials coupled to translational endpoints have been developed through inter-programmatic collaborations with other Programs, including Oncoimaging (Neoadjuvant breast), and Cacinogenesis and Signaling (CML, prostate). Over the past five years, our Program has focused on accrual to clinical research trials, including Hypothesis-driven, investigator-initiated trials (HDII), cooperative group, and pharmaceutical sponsored trials. Emphasis has been placed on HDII trials to exploit UCI's rich Comprehensive Cancer Center resources to develop novel approaches to cancer care. HDII accrual over the past six years has grown dramatically from 60 in 2002-2004 to 175 in 2005-2007. Overall interventional clinical trials accrual, excluding chemoprevention trials, was 142 in 2002-2003, increasing to 218 in 2004-2005, and 387 to date in 2005-2007, Of particular significance, this growth in accrual was linked to translational endpoints that led to peer reviewed funding and increased numbers of publications in high impact journals. The TO Program has 25 Members, representing eight Departments and one School, and has $2,024,203 in direct cancer-related peer-reviewed funding, 10 projects of which are funded by NCI for a direct total of $1,187,498. In 2007, Members published a total of 71 publications with 62 of those being cancer-related of which 44% were inter- and 16% were intra-related.